"Disrupting the Pairing Between let-7 and Hmga2 Enhances Oncogenic Transformation".

Christine Mayr ¹, Michael T. Hemann ², and David P. Bartel ^1, *

¹ Howard Hughes Medical Institute and Department of Biology, Massachusetts Institute of Technology, and Whitehead Institute for Biomedical Research, 9 Cambridge Center, Cambridge, MA 02142, USA.
² Center for Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.

*To whom correspondence should be addressed. E-mail: dbartel@wi.mit.edu

Hmga2 codes for a small, non-histone, chromatin-associated protein that has no intrinsic transcriptional activity but can modulate transcription by altering the chromatin architecture (1, 2). Hmga2 is primarily expressed in undifferentiated proliferating cells during embryogenesis and in a wide variety of benign and malignant tumors (3–6). In many of these tumors a chromosomal translocation at 12q15 truncates the human HMGA2 open reading frame (ORF), typically retaining the three DNA-binding domains of HMGA2 while
replacing the spacer and the acidic domains at the C-terminus by any of a large variety of ectopic sequences (3–5, 7–11) (Fig. 1A).

Fig. 1. Chromosomal translocations involving HMGA2, and the influence of let-7 on protein expression.

Fig. 1. Chromosomal translocations involving HMGA2, and the influence of let-7 on protein expression.

(A) Translocations involving HMGA2 and numerous translocation partners (3-11). These translocations generate a truncated HMGA2 mRNA lacking the let-7 complementary sites of the wild-type mRNA and are associated with the indicated tumors. In its 3' UTR, human HMGA2 has seven let-7 complementary sites, all of which are conserved in mouse, rat, dog, and chicken (15).

(B) RNA blot detecting let-7 RNA in different cell lines. The blot was reprobed for U6 snRNA, and let-7 signal normalized to that of U6 is indicated.

(C) Western blot monitoring endogenous Hmga2 48 hours after transfection of F9 cells with the indictated miRNA duplex. The blot was probed also for GAPDH, and the normalized Hmga2 signal is indicated.

(D) Western blot monitoring endogenous Hmga2 24 (left) and 48 (right) hours after transfection of NIH3T3 cells with the indictated 2'-O-methyl oligonucleotide (2'-O-Me). The blot was probed also for GAPDH, and the normalized Hmga2 signal is indicated.

The Hmga2 3' UTR has seven conserved sites complementary to the let-7 RNA (15), a miRNA expressed in later stages of animal development (16), leading us to suspect that disrupting let-7 regulation of Hmga2 might lead to oncogenic transformation. Consistent with this idea, introducing let-7 RNA repressed Hmga2 in F9 cells (Fig. 1C), an undifferentiated embryonic carcinoma cell line that does not express detectable let-7 RNA (Fig. 1B). Moreover, introducing a 2'-O-methyl oligonucleotide (17) complementary to let-7 RNA enhanced Hmga2 in NIH3T3 cells (Fig. 1D), a cell line that naturally expresses let-7 (Fig. 1B). These effects were specific in that they did not occur with noncognate miRNAs (mlet-7 and miR-101, Fig. 1C) or a noncognate inhibitor (miR-124 2'-O-Me, Fig. 1D).

To test whether let-7 directly targets the Hmga2 3' UTR, reporters were constructed with the wild-type 3' UTR (Luc-wt) and the UTR with point mutations disrupting all seven sites (Luc-m7), the four distal sites (Luc-m4) or the two most distal sites (Luc-m2) (Fig. 2A).

Fig. 2. Luciferase reporter assays showing the influence of miRNA-target pairing.

Fig. 2. Luciferase reporter assays showing the influence of miRNA-target pairing.

(A) Design of Luciferase constructs. The 3' UTR of murine Hmga2 was appended to the Luciferase ORF (Luc). let-7 complementary sites are indicated (vertical red lines), as are mutant sites (black Xs). The Luc-m7, Luc-m4 and Luc-m2 were identical to Luc-wt, except they had seven, four and two mutant sites, respectively. Each mutant site had two point substitutions that disrupted pairing to let-7 but created pairing to mutant let-7 (mlet-7, lower panel). The seven sites were identified in a search for conserved 7-8mers matching the seed region of let-7 (15).

(B) Reporter repression in F9 cells supplemented with the indicated miRNA. Bars are colored to indicate the number of sites mutated in the reporter. Shown are median repression values, with error bars indicating 25th and 75th percentiles; n = 12, except experiments with no added miRNA (–), in which n = 36. Within each quartet, activity was normalized to that of the Luc-m7 reporter, except for the mlet-7 quartet, for which
activity was normalized to that of the Luc-m7 reporter with noncognate miRNA (miR-124).

(C) Reporter repression in NIH3T3 cells (upper panel) or HeLa cells (lower panel) supplemented with the indicated miRNA, performed and displayed as in (B). We also noticed two additional let-7 complementary sites in the murine Hmga2 mRNA, but located in the 5' UTR. When tested in luciferase reporter assays, these sites mediated little or no repression in the different cell lines, and the mutant sites did not respond to
mlet-7 indicating that any effects observed with the 5' UTR sites were not miRNA specific.

In F9 cells, the degree of repression corresponded to the number of intact sites and depended on co-transfection of the let-7 miRNA, whereas co-transfection of an unrelated miRNA had little effect (miR-124, Fig. 2B). The repression profile inverted when the let-7 miRNA was replaced with a mutant miRNA, mlet-7 (Fig. 2B), which was designed to recognize the mutant sites instead of the wild-type sites (Fig. 2A). This rescue of repression with compensatory changes in the miRNA confirmed targeting specificity and the importance of direct pairing between the sites and the miRNA.

To examine repression directed by endogenous let-7, the reporter assays were repeated using NIH3T3 cells and HeLa cells, which naturally express let-7 (Fig. 1B). In both cell types, reporter repression depended on the wild-type sites, as expected if the endogenous let-7 miRNA directed repression (Fig. 2C). Adding exogenous let-7 RNA enhanced repression, suggesting that let-7 RNA was subsaturating in these cells.
Adding mutant let-7 caused reporters with mutant sites to also be repressed. Adding mlet-7 or miR-124 decreased repression of the reporter with wild-type sites (particularly in HeLa cells), as if the transfected miRNA was competing with endogenous let-7 RNA for a limiting factor.

Having established that the sites within the Hmga2 3' UTR could mediate let-7-directed repression, we tested whether disrupting this repression could promote oncogenic transformation. Assays for anchorage-independent growth were performed with NIH3T3 cells, which form colonies in soft agar when stably transfected with a potent oncogene. Stably transfecting a vector expressing wild-type Hmga2 did not significantly increase the number of colonies, compared to transfecting an empty vector, whereas transfecting a vector expressing a truncated Hmga2 (Hmga2-tr; Fig. 3A), shown previously to promote anchorage-independent growth (18), produced significantly more colonies (Fig. 3B).

Fig. 3. Soft-agar assay for anchorage-independent growth.

Fig. 3. Soft-agar assay for anchorage-independent growth.

(A) Hmga2 constructs used for stable transfection, depicted as in Fig. 2A and described in the text.

(B) Colony formation. For cells stably transfected with the indicated vector, the percentage that yielded colonies after 28 days is plotted (median, horizontal line; 25th through 75th percentile, box; range, error bars; n = 12 from four independent experiments, each in triplicate). All but Hmga2-wt yielded a significantly
higher number of colonies than did the empty vector (Mann-Whitney test for each, P < 0.05). When compared to Hmga2-wt, a significantly higher number of colonies was observed for Hmga2-tr (P = 0.003). Hmga2-m7 showed significantly more colonies than any of the other constructs tested (P < 0.05 for each; *, P = 0.041; **, P = 0.002; ***, P = 10^-6 ). No significant difference was observed between Hmga2-wt and
the construct with the truncated ORF (P = 0.61).

As in human tumors, Hmga2-tr lacked the spacer, the acidic domain and the entire 3' UTR with its miRNA complementary sites (Fig. 3A). The increase in colonies was attributed to the loss of let-7 repression rather than the truncation of the protein because stably expressing Hmga2-m7, which had the full ORF but
disrupted let-7 complementary sites (Fig. 3A), produced at least as many colonies as Hmga2-tr, whereas stably expressing Hmga2-ORFtr, which had the truncated ORF but intact miRNA complementary sites (Fig. 3A), produced a number comparable to that of Hmga2-wt (Fig. 3B). Stably expressing Hmga2-m4, which retained the first three let-7 sites, led to an intermediate number of colonies.

We next tested whether the stably transfected cells used to assay anchorage-dependent growth were also able to form subcutaneous tumors in nude mice. Consistent with our soft-agar results, tumors were observed when injecting cells expressing constructs with mutated let-7 sites: after five weeks three of four mice injected with Hmga2-m7 cells and two of four mice injected with Hmga2-m4 cells had tumors at the sites of injection. One of four injected with Hmga2-tr cells and one of four injected with Hmga2-ORFtr also had
tumors, whereas no tumors were observed five weeks after injecting cells stably transfected with either wild-type Hmga2 or empty vector.

Taken together, our results support the proposal that the let-7 miRNA acts as a tumor-suppressor gene (19, 20) and indicate that a major mechanism of oncogenic Hmga2 translocations associated with various human tumors is the loss of let-7 repression. Thus, loss of miRNA-directed repression of an oncogene is another type of oncogene-activating event that should be considered when investigating the effects of mutations associated with cancer. Likewise, mutations that create miRNA-directed repression of tumor-suppressor
genes might also impart a selective advantage to the tumor cells. In this regard, we note that Hmga2
translocations frequently append the Hmga2 3' UTR to the 3' end of known tumor-suppressor genes, including FHIT, RAD51L1, or HEI10 (5, 8, 9), suggesting that let-7-directed repression of these translocation partners might cooperate with disrupting Hmga2 repression to promote tumorigenesis.

Vertebrate miRNAs can each have hundreds of conserved targets and many additional nonconserved targets (15, 21–25), which all have confounded exploration of the biological impact of particular miRNA-target relationships. In worms, flies and plants, repression of particular targets is known to be
relevant because genetic studies have investigated what happens when that target alone is not repressed by the miRNA (26–28). Because of the possibility that multiple interactions might need to be perturbed to observe a phenotypic consequence in mammals, it has been unclear whether the importance of a particular mammalian miRNA-target interaction can be demonstrated experimentally. Our results, combined with previous cytogenetic studies that speak to the effect of misregulating the endogenous human HMGA2 gene, show that disrupting miRNA regulation of Hmga2 enhances oncogenic transformation, thereby
demonstrating that disrupting miRNA regulation of a single mammalian gene can have a cellular phenotype in vitro and a clinical phenotype in vivo.

References and Notes

1. R. Sgarra et al., FEBS Lett. 574, 1 (2004).

2. M. Fedele et al., Oncogene 21, 3190 (2002).

3. E. F. Schoenmakers et al., Nat. Genet. 10, 436 (1995).

4. J. M. Geurts, E. F. Schoenmakers, W. J. Van de Ven, Cancer Genet. Cytogenet. 95, 198 (1997).

5. N. Mine et al., Jpn. J. Cancer Res. 92, 135 (2001).

6a. M. Fedele et al., Carcinogenesis 22, 1583 (2001).

6b. Carla Hebert, Kathleen Norris, Mark A Scheper, Nikolaos Nikitakis, and John J Sauk,
High mobility group A2 is a target for miRNA-98 in head and neck squamous cell carcinoma,
Molecular Cancer 2007, 6:5     doi:10.1186/1476-4598-6-5
http://www.molecular-cancer.com/content/6/1/5

7. M. M. Petit, R. Mols, E. F. Schoenmakers, N. Mandahl, W. J. Van de Ven, Genomics 36, 118 (1996).

8. E. F. Schoenmakers, C. Huysmans, W. J. Van de Ven, Cancer Res. 59, 19 (1999).

9. J. M. Geurts, E. F. Schoenmakers, E. Roijer, G. Stenman, W. J. Van de Ven, Cancer Res. 57, 13 (1997).

10. N. Inoue et al., Blood 108, 4232 (2006).

11. Supporting Online Text

12. L. Borrmann, S. Wilkening, J. Bullerdiek, Oncogene 20, 4537 (2001).

13. S. Battista et al., Cancer Res. 59, 4793 (1999).

14. G. Baldassarre et al., Proc. Natl. Acad. Sci. U S A 98, 7970 (2001).

15. B. P. Lewis, C. B. Burge, D. P. Bartel, Cell 120, 15 (2005).

16. A. E. Pasquinelli et al., Nature 408, 86 (2000).

17. G. Hutvagner, M. J. Simard, C. C. Mello, P. D. Zamore, PLoS Biol. 2, E98 (2004).

18. M. Fedele et al., Oncogene 17, 413 (1998).

19a. S. M. Johnson et al., Cell 120, 635 (2005).

19b. Eder M, and Scherr M, "MicroRNA and Lung Cancer", (2005).

20a. J. Takamizawa et al., Cancer Res. 64, 3753 (2004).

20b. Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, Stephens RM, Okamoto A, Yokota J, Tanaka T, Calin GA, Liu C-G, Croce CM, and Harris CC,  "Unique microRNA molecular profiles in lung cancer diagnosis and prognosis", Cancer Cell, vol 9, no. 3, pp. 189-198 (March, 2006).

21. A. Krek et al., Nat. Genet. 37, 495 (2005).

22. L. P. Lim et al., Nature 433, 769 (2005).

23. K. K. Farh et al., Science 310, 1817 (2005).

24. J. Krutzfeldt et al., Nature 438, 685 (2005).

25. A. J. Giraldez et al., Science 312, 75 (2006).

26. B. Wightman, I. Ha, G. Ruvkun, Cell 75, 855 (1993).

27. E. C. Lai, B. Tam, G. M. Rubin, Genes Dev. 19, 1067 (2005).

28. M. W. Jones-Rhoades, D. P. Bartel, B. Bartel, Annu. Rev. Plant Biol. 57, 19 (2006).

29. We thank M. Narita and S. Lowe for generously providing the Hmga2 antibody, and C. Jan, A. Grimson,
and M. Narita for helpful discussions and advice.

Supported by grants from the DFG (C.M.) and the NIH (D.B.). D.B. is an HHMI Investigator.

http://www.sciencemag.org/cgi/content/full/1137999/DC1

Materials and Methods
SOM Text
Figs. S1 and S2
Supporting References

A  finely analyzed clinical study by Yanaihara N. et al., (2006) shed new light on the possibility that non-small cell lung cancer  (NSCLC) may be a miRNA-deficiency disease. This concept arose when earlier retrospective studies of the lung tissue from NSCLC patients, who had been resected many years before, showed that patient survival was adversely affected by a deficiency of embryonic let-7 miRNA species in the pre-operative tumor. That study also showed that replenishing let-7 miRNA activity in NSCLC cell cultures by administered plasmids normalized the elevated in-vitro growth rates of NSCLC cells. A review of the subject suggested that administration of let-7 miRNA to NSCLC cells might reprogram the cancer cells toward normality in culture. Interest increased when it was discovered that let-7 miRNA decreased the activity of RAS oncogenes in cultured cells and neoplasms, and the analysis of specific microRNA species for cancer therapy was discussed in many research centers. More recently it was discovered in the study by Yanaihara, N., et al, (2006), that only one type of the let-7 miRNA family (hsa-let-7a2 microRNA) is effective in improving the survival of NSCLC patients in retrospective clinical studies, and a new study reveals that a closely-related let-7 miRNA (hsa-let-7a-3) may actually be oncogenic in retrospective studies. That data suggested that the two forms of let-7a miRNA may interactwith each other in vivo, (thus neutralizing the effectiveness of  hsa-let7a2), but no data on this possibility was then available. Now, in this beautiful study by Christine Mayr, Michael Hemann, and David Bartel, it is shown that specific nucleotide base-pairing between the embryonic let-7 miRNA repressor and the embryonic oncogene Hmg mRNA results in decreased growth rates of cultured human cancer cells.
In 1963, De Carvalho showed that transfusion of normal total bone marrow RNA from human volunteers resulted in clinical and marrow responses in 3 patients with acute myelogenous leukemia in relapse.

Additional References:

0. Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, Stephens RM, Okamoto A, Yokota J, Tanaka T, Calin GA, Liu C-G, Croce CM, and Harris CC,  "Unique microRNA molecular profiles in lung cancer diagnosis and prognosis", Cancer Cell, vol 9, no. 3, pp. 189-198 (March, 2006).

1. Takamizawa, J., Konishi, H., Yanagisawa, K., Tomida, S., Osada, H., Endoh, H., Harano, T., Yatabe, Y., Nagino, M., Nimura, Y., Mitsudomi T,  and Takahashi T,  (2004). Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res. 64, 3753–3756, (2004).

2. Hovsepian JA, and Frenster JH, "Reprogramming as an Approach to Neoplasms", (2004).

3. Johnson, S.M., Grosshans, H., Shingara, J., Byrom, M., Jarvis, R., Cheng, A., Labourier, E., Reinert, K.L., Brown, D., and Slack, F.J. RAS is regulated by the let-7 microRNA family. Cell 120, 635–647, (2005).

4. Eder M, and Scherr M, "MicroRNA and Lung Cancer", (2005).

5. Brueckner B, Stresemann C, Kuner R, Mund C, Musch T, Meister M, Sultmann H, and Lyko F, (2007). The human let-7a-3 locus contains an epigenetically regulated microRNA gene with oncogenic function.
Cancer Res. 67: 1419-1423, (2007).

Frenster JH, "Oncogenes as Molecular Targets within Active Chromatin". (1999).

Hayes GD, and  Ruvkun G,  "Misexpression of the Caenorhabditis elegans miRNA let-7 is Sufficient to Drive Developmental Programs". (2006).

6. DeCarvalho S, "Effect of RNA from Normal Human Marrow on Leukaemic Marrow In-Vivo", (1963).
 

Links to Euchromatin Activator RNA Reviews:
Links to Euchromatin Activator RNA Research:
Links to Ultrastructural Probes of DNase I-Sensitive Sites:
Links to RNA as a Therapeutic Agent:
Links to Hodgkin Lymphoma Immuno-Pathology:
Links to Activated T-Lymphocyte Immunotherapy:
Links to Medical Systems Biology:
Links to Selective Gene Transcription:
Links to RNA-Induced Epigenetics:
Links to RNA-Induced Embryogenesis:
Links to RNA and Biological Causality:
Links to Reprogramming and Neoplasia:

A Brief History of Activator RNA:

"Ultrastructural Probes of Active DNA Sites, and the RNA Activators of DNA". (PowerPoint Presentation).